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Background: Previous research has shown that innate immune system was more important than
the acquired immune system in the pathogenesis of COPD. LL-37 is the only human cathelicidin
identified so far. As an integral part of the innate immune system, besides antibacterial
activity, its chemotactic activity, damage repairing, influencing apoptosis and its cytotoxicity
are attracting people’s attention. The aim of the present study was to evaluate role of LL-37 in
the pathogenesis of COPD.
Methods: ELISA and immunohistochemistry were applied to investigate the expression of LL-37
in induced sputum and lung tissue of COPD patients. Bronchial epithelial cell (BEP2D) and alve-
olar epithelial cell (A549) were treated with LL-37 synthesis polypeptide in vitro to assess the
role of LL-37 in inflammation and apoptosis.
Results: We found that increased induced sputum levels of LL-37 in COPD patients were asso-
ciated with airflow limitation, health status and exercise tolerance and the expressing inten-
sity of LL-37 in both airway district and pulmonary alveoli area in COPD group significantly
increased compared with control group. Through stimulation by CSE and LPS, the expression
of LL-37 was increased in bronchial epithelial cell and alveolar epithelial cell. LL-37 synthesis
polypeptide can promote the releasing of inflammatory factor IL-8 and induce apoptosis of
bronchial epithelial cell and alveolar epithelial cell.
Conclusion: This study suggested that LL-37 may play important role in the pathogenesis of
COPD and may be a possible novel therapeutic target in COPD.
ª 2012 Elsevier Ltd. All rights reserved.3678801528.
3.com, xiaowei810823@yahoo.cn (W. Xiao).
2 Elsevier Ltd. All rights reserved.
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Effect of human antibacterial peptide LL-37 on COPD 1681Chronic obstructive pulmonary disease is one of the leading
causes of morbidity and mortality worldwide, and its
purulence and sputum volume) or in one major and one
minor symptom (wheeze, sore throat, cough and symptomsprevalence is increasing. Progressive airflow limitation and
symptoms in COPD are associated with an abnormal
inflammatory response of the lung to noxious particles or
gases.1
The innate immune system of the lung protects against
infection and regulates inflammatory responses and adap-
tive immunity. Various studies have highlighted the role of
the innate immune system in COPD.2,3 Antimicrobial
peptides (AMPs) are now considered as an essential part of
innate immunity because of their ability of killing invading
respiratory pathogens and their various other activities.
The defensins and cathelicidins are the principal compo-
nents of AMPs families. LL-37 is the only human cathelicidin
identified so far.4 As an integral part of the innate immune
system, this protein is involved in the first line of host
defense. LL-37 displays antimicrobial activity against Gram-
positive and Gram-negative bacteria, fungi and viruses,
neutralizes LPS bioactivity, and so protects against endo-
toxic shock.5,6 Besides antibacterial activity, its chemo-
tactic activity, damage repairing, influencing apoptosis and
its cytotoxicity are attracting people’s attention.7e13
Chronic inflammation and airway remodeling are properly
two main pathological processes in the pathogenesis of
COPD. Previous studies of our team showed that LL-37 is
elevated in induced sputum in COPD patients and inversely
related to lung function.14,15 We presume that with the
wide spectrum and multi-effect biological function, LL-37
may play important role in the pathogenesis of COPD.
In this study, we thus examined the expression of LL-37
in induced sputum and lung tissue of COPD patients and
assessed the possible role of LL-37 in inflammation and
apoptosis.Patients and methods
Patients and controls
A total of 60 subjects, including 28 stable COPD patients, 14
healthy current smokers and 18 healthy non-smokers were
enrolled in this study. The lung tissues from 9 COPD patients
and 10 controls receiving operation because of lung cancer,
lung bullae, lung cyst from an uninvolved segment of the
subpleural parenchyma at least 5 cm away from diseased
region were collected for immunohistochemical staining.
The diagnosis of these COPD patients was made according
to the criteria of global initiative for chronic Obstructive
Lung Disease (GOLD 2007). All patients were recruited from
hospitalized or the Outpatients Department at Qilu
Hospital, Shandong University, China. 14 healthy current
smokers and 18 healthy non-smokers are health care
workers of our hospital. All participants met the following
criteria: no exacerbation, no use of inhaled or oral corti-
costeroids for 3 months prior to sample collection, and no
respiratory tract infection for 1 month before the study.
Patients with bronchiectasis, asthma, interstitial diseases
and heart failure were excluded. An exacerbation was
defined as the presence, for 2 days consecutively, of an
increase in any two major symptoms (dyspnea, sputumof a common cold).16,17 The study was approved by the
Ethics Committee of Shandong University, and written
informed consent was acquired from each individual.
Cell lines and culture conditions
BEP2D (ATCC) was cultured at 37 C in 5% CO2 in LHC-8
(GIBCO, GrandIsland, NY). The AECs (A549 cells) were
cultured in DMED supplemented with 10% fetal bovine
serum (FBS), penicillin (100 units/mL), and streptomycin
(100 mg/ml) at 37 C in 5% CO2. The culture medium was
changed every 2 days. Cells were passaged every 4e5 days
with 0.25% trypsin (Sigma, USA).
Reagents
Kentucky standard reference cigarettes 2R4F were used for
cigarettes smoke extraction (CSE). The cigarettes were
conditioned at 22 C and 60% relative humidity for at least
48 h before use. JJD100 single channel smoking machine
was used with parameter of once per 2 s and 1 min’
intervals. Cigarette smoke was diluted in D-hanks and
filtered through a 0.22 mm-pore filter to remove bacteria
and stored in 80 C.
Lipopolysaccharides (LPS) (Sigma, USA) was diluted in
serum-free DMEM into 100 mg/mL and filtered through
a 0.22-mm-pore filter to remove bacteria.
LL-37 polypeptide (amino acid sequence: LLGDFFRKSKE-
KIGKEFKRIVQRIKDFLRNLVPRTES) was synthesized by GL Bio-
chem (Shanghai) Ltd in China.
Pulmonary function, health status and exercise
tolerance
Pulmonary function was measured using a spirometer
(Jaeger, Hoechberg, Germany), according to standardized
guidelines.18 Measurements were always performed by the
same technician using the same spirometer. Health status
was assessed using the St. George’s Respiratory Question-
naire (SGRQ).19 Scores were based on a scale of 0e100, with
lower scores indicating better health status. The 6MWD was
used to evaluate patients’ exercise tolerance. Subjects
were given standardized instructions to walk the greatest
distance possible in 6 min and were given verbal encour-
agement. The 6MWD test was performed according to the
American Thoracic Society guidelines.20
Collection and preparation of blood samples
Peripheral venous blood samples (5 mL) were taken and
were centrifuged at 13,000 g for 15 min at 4 C. Serum was
aspirated and frozen at 80 C for subsequent analysis.
Sputum induction and processing
After measurement of pulmonary function, salbutamol was
administered (200 mg by metered-dose inhaler), and 15 min
later subjects inhaled hypertonic (4%) saline delivered by
1682 Y.-Y. Jiang et al.an ultrasonic nebulizer (DeVilbiss 65; DeVilbiss Corporation,
Somerset, PA, USA).21e24 Subjects were encouraged to
cough, and sputum was collected in clean polypropylene
cups. The sputum specimen was examined within 2 h and
the viscous portions were selected and weighed. A freshly
prepared 1:10 dilution of dithiothreitol (DTT; Sputolysin;
Calbiochem Corp., San Diego, CA, USA) in distilled water
was added in a volume equal to four times the weight of the
selected sputum specimen. Samples were placed in
a shaking water bath at 37 C for 15 min, then further
diluted with PBS to a volume equal to the sputum plus DTT.
The suspension was filtered through gauze to remove
mucus, and centrifuged at 120 g for 8 min. The supernatant
was aspirated and frozen at 80 C for subsequent analysis.
The cell pellet was suspended in a volume of PBS equal to
that of the aspirated supernatant. The total cell count and
viability (Trypan blue exclusion method) were determined
using a hemocytometer. Only samples with cell viabilities
>50% and <20% squamous cell contamination were
included in the analysis.
Measurement of LL-37 in serum and induced
sputum
The concentrations of LL-37 in serum and induced sputum
supernatants were assayed using commercial ELISA kits
according to the manufacturers’ instructions. (LL-37:
Hycult Biotechnology, Uden, the Netherlands). All assays
were performed in duplicate for each sample, and the
mean values are reported.
Cell viability test
Cell viability was measured by the MTT assay based on the
protocol described previously. BEP2D and A549 were
seeded in 96-well culture plate at a density of
1  104 cells/well in a final volume of 100 ml medium.
Approximately 24 h after seeding, CSE and LPS were added
to the well at different concentrations for 6, 12, 24, 48 h.
After treatment, culture medium was removed and 10 mg of
MTT (0.5 mg/ml) dissolved in culture medium was added
and incubated for 4 h at 37 C. 100 ml dimethyl sulfoxide
(DMSO) was added to each well. Plates were gently shaken
for 10 min and the absorbance was recorded at 560 nm
using a microplate spectrophotometer (BIO-RAD Mode 680,
CA, USA). The cell viability was expressed as the
percentage of absorbance of treated group to untreated
control group.
Immunohistochemical staining and double
immunofluorescence staining
LL-37 in human lung tissues was examined by immunohis-
tochemistry. Formalin fixed paraffin-embedded lung tissue
sections were stained with rabbit anti-human LL-37
(Abcam, USA) and biotinylated goat anti-rabbit Ig (Maixin
Co., Fuzhou, China) followed by streptavidin-conjugated
peroxidase. DAB was used as substrate. Positive cells were
counted in 50 different fields by 2 independent observers.
For double immunofluorescence staining, BEP2D and A549
were incubated with anti-LL-37-FITC and DAPI for 60 min atroom temperature successively and then determined by
laser scanning confocal microscope. Immunostaining was
evaluated with the guidance of a pathologist who did not
have access to the study. The mean of the data from two
different observers was calculated.Measurement of IL-8 and TNF-a levels in cell
culture supernatants
BEP2D and A549 cells were cultured with serum-free DMEM
containing different concentration LL-37 polypeptide for
24 h. Then the supernatants were harvested. IL-8 and TNF-
a were quantified by ELISA kits supplied by R&D as the
manufactures’ instruction.Flow cytometry analysis of apoptosis with Annexin
ⅤeFITC/PI staining
Apoptosis assay was performed by flow cytometry according
to the manufacturer’s protocol (BD BioScience, San Jose,
USA). Briefly, cells from 70% confluent plate were treated
with different concentration of LL-37 polypeptide. The
harvested cells were washed twice with cold PBS, and
suspended in binding buffer. Aliquots of 100 ml suspension
(1  105 cells) was incubated with 5 ml Annexin V-FITC and
5 ml PI for 15 min at room temperature in the dark. Cell
suspension was added with 400 ml of binding buffer, gently
vortexed, and analyzed within 1 h by flow cytometry
(BectoneDickinson, Oxford, UK). Apoptotic cells were
expressed by percentage of Annexin V-FITC-positive cells of
total gated cells.Statistical analysis
All data were analyzed using the SPSS 16.0 software. The
KruskaleWallis nonparametric H test and ManneWhitney
nonparametric U test were used for comparison of LL-37 in
induced sputum between groups. Correlations between LL-
37 and pulmonary function parameters, SGRQ scores and
6MWD were assessed by Spearman’s rank correlation test.
Independent sample t-test and ANOVA were used to
compare quantitative variables. Chi-square test and
Fisher’s exact test were used to compare categorical vari-
ables .A P-value <0.05 was considered significant.Results
Clinical data
COPD patients were divided into I þ II COPD and III þ IV
COPD according to FEV1%. All subjects were well matched
for age and gender. Smoking histories were not significantly
different between healthy smokers and COPD patients.
FEV1%, FEV1/FVC and 6MWD were significantly lower in
COPD patients compared with healthy non-smokers and
healthy smokers (p < 0.05, Table 1). SGRQ scores were
significantly higher in COPD patients than in the other two
groups (p < 0.05, Table 1).
Table 1 Clinical data for the subjects included for serum and sputum detection.
Healthy non-smokers Healthy smokers I þ II COPD III þ IV COPD
n 18 14 13 15
Age (years) 63.1  7.4 60.1  9.8 61.8  7.9 63.5  9.2
Male/female 12/6 9/5 9/4 9/6
Smoking history (pack-years) 0 43.6  23.7 42.8  26.8 46.9  27.4
FEV1% 90.4  8.5 84.1  7.8 57.1  6.9 23.4  5.8
FEV1/FVC 77.6  6.8 74.9  4.7 54.6  7.6 34.1  7.2
SGRQ scores 2.5  1.5 3.5  1.5 20.5  8.5 45.7  7.6
6MWD 539.5  86.3 529.6  68.1 456.2  70.5 420.5  87.5
Data are presented as mean  SD.
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To study the expression of LL-37 in serum and induced
sputum, we performed ELISA analysis in 28 COPD patients,
18 healthy non-smokers and 14 healthy smokers. As shown
in Fig. 1, induced sputum LL-37 levels were significant
higher in I þ II COPD and III þ IV COPD patients compared
with healthy non-smokers and healthy smokers (I þ II COPD
patients vs III þ IV COPD patients vs healthy non-smokers vs
healthy smokers Mean  SD 4.37  4.19 ng/ml,
7.99  4.01 ng/ml, 0.74  0.61 ng/ml, 2.64  1.93 ng/ml,
p < 0.05). The expression of LL-37 was elevated in III þ IV
COPD patients compared to I þ II COPD patients (p < 0.05),
LL-37 levels were significant higher in healthy smokers than
healthy non smoker while there were no statistically
significant differences in serum LL-37 levels between these
four groups (I þ II COPD patients vs III þ IV COPD patients vs
healthy non-smokers vs healthy smokers Mean  SD
0.46  0.14 ng/ml, 0.49  0.14 ng/ml, 0.47  0.18 ng/ml,
0.51  0.16 ng/ml).
Correlation analysis
To examine the potential role of LL-37 in disease activity or
progression, LL-37 levels were correlated with pulmonary
function as determined by FEV1%, SGRQ scores and 6MWD.
Sputum LL-37 levels in COPD patients showed inverse
correlation with FEV1% (r Z 0.32, P Z 0.01) and 6MWDFigure 1 Concentrations of LL-37 in serum (A) and induced spu
patients. Data were analyzed using one-way analysis of variance o
smokers; #p < 0.05 compared with healthy smokers; & p < 0.05 c(r Z 031, P Z 0.01), and positive correlation with SGRQ
scores (r Z 0.35, P Z 0.01).Expressions of LL-37 in lung tissue
The clinical characteristics of the subjects for Immunohis-
tochemical staining are shown in Table 2. All subjects were
well matched for age and gender. Smoking histories, FEV1%,
FEV1/FVC% were not significantly different between COPD
patients and control. LL-37 in lung tissue was mainly
expressed on bronchial epithelial cell, alveolar epithelial
cell, inflammatory cell (including neurophils, monocyte-
macrophage and lymphocyte) and fibroblast. The express-
ing intensity of positive cell in both airway area and
pulmonary alveoli area in COPD group was significantly
higher than that in control group (Fig. 2).Cytotoxicity induced by CSE and LPS
To examine the toxic effects of CSE and LPS on cell
viability, BEP2D and A549 cells were incubated with
different concentration of CSE or LPS for 6, 12, 24, 48 h. As
shown in Fig. 3, cell viability decline in both concentration-
and time-dependent manners. According to these results,
we selected 0.02 cig/ml, 0.04 cig/ml, 0.06 cig/ml of CSE
and 10 mg/ml, 20 mg/ml, 30 mg/ml of LPS in the subsequent
experiments.tum (B) of healthy non-smokers, healthy smokers, and COPD
r nonparametric tests. *p < 0.05 compared with healthy non-
ompared with I þ II COPD patients.
Table 2 Clinical data for the subjects included for immunohistochemical staining.
n Age Male/female Smoking history (pack-years) FEV1% FEV1/FVC%
Control 10 56.4  7.9 6/4 54.0  35.8 110.4  17.3% 82.6  8.3%
COPD 9 60.1  8.6 5/4 53.6  35.2 61.63  15.9% 56.3  10.5%
Data are presented as mean  SD.
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To investigate whether CSE and LPS can induce LL-37
expression, we assessed the levels of LL-37 in the protein
levels through immunofluorescence staining with Confocal
Laser Scanning Miccruscope (CLSM). The results of CLSM
showed that expression of LL-37 was gradually increased
after incubated 24 h with 0.02 cig/ml, 0.04 cig/ml, 0.06 cig/
ml of CSE or 10 mg/ml, 20 mg/ml, 30 mg/ml of LPS (Fig. 4).
Effects of LL-37 synthesis polypeptide on the
release of IL-8 and TNF-a of BEP2D and A549
To explore the role of LL-37 synthesis polypeptide on
inflammatory factors releasing, we assessed the levels of
IL-8 and TNF-a in supernatants of BEP2D and A549 afterFigure 2 Representative light photomicrographs of immunostain
alveolar areas (C, D) in lung tissue from COPD patient (A, C) and cincubated with different concentration of LL-37 synthesis
polypeptide by ELISA. As shown in Fig. 5, IL-8 were
increased gradually in the supernatants of BEP2D and A549
after incubated with 10 mg/ml of LL-37 synthesis poly-
peptide while the level of TNF-a was not effected by LL-37
synthesis polypeptide.
Analysis of LL-37-induced apoptosis by flow
cytometry
Using fluorescent prone Annecin VeFITC and PI, apoptotic
and necrotic cells were determined by flow cytometry
analysis. The scatter plot of Annecin VeFITC and PI showed
that LL-37 synthesis polypeptide can induce apoptosis of
BEP2D and A549, showing dose and time-dependent effect
(Fig. 6).ing for LL-37 (brown staining) in small airway areas (A, B) and
ontrol (B, D).
Figure 3 Effect of CSE and LPS on the viability of BEP2D and A549. A. Viability of BEP2D cells after treated with the indicated
doses of CSE for 6 h, 12 h, 24 h, 48 h. B. Viability of A549 cells after treated with the indicated doses of CSE for 6 h, 12 h, 24 h, 48 h.
C. Viability of BEP2D cells after treated with the indicated doses of LPS for 6 h, 12 h, 24 h, 48 h. D. Viability of A549 cells after
treated with the indicated doses of LPS for 6 h, 12 h, 24 h, 48 h.
Effect of human antibacterial peptide LL-37 on COPD 1685Discussion
LL-37, the only member of cathelicidins’ family found in
humans, was isolated from human bone marrow in
1995.25e27 LL-37 is produced by neutrophils, macrophages
and respiratory epithelial cells. The antimicrobial domain is
released by cleavage by proteases and this domain is
termed LL-37. In the present study, in order to explore the
possible role of LL-37 in the pathogenesis of COPD, we thus
first examined the expression of LL-37 in induced sputum
and lung tissue of COPD patients and then explored the
possible mechanism of LL-37 in COPD in vitro.
We initially found that LL-37 levels in induced sputum in
COPD patients were significantly higher than control
subjects and there were inverse correlations between
sputum LL-37 levels and FEV1% and 6MWD, and a positive
correlation between sputum LL-37 levels and SGRQ scores.
Another research published in 2009 which similar to ours
also showed high Cathelicidin LL-37 levels in induced
sputum from farmers with COPD.28 These results suggested
a potential role for LL-37 in COPD.
The differences in sputum levels may have resulted from
local production due to an airway inflammatory response.
However, why the levels of LL-37 were raised up in stable
COPD patients while there was no significant infection in
these people? In order to explore the source of LL-37, we
examine the expression of LL-37 in lung tissues of COPD
patients with immunohistochemistry. The results showed
that LL-37 was mainly localized in bronchial epithelial cell,
alveolar epithelial cell, inflammatory cell and fibroblast.
The expressing intensity of positive cell in COPD group was
significantly higher than that in control group. This result
was consistent with the previous reports that LL-37 was
expressed on respiratory epithelium and neutrophils.29
Therefore, these results explained the abnormal increase
of LL-37 in induced sputum in COPD patients was not simplebecause of the high rate of neutrophils, but an immune
response resisting outside stimulation that many cells
participated. Bronchial epithelial cell and alveolar epithe-
lial cell, as important components of innate immune
system, play an important role in these processes which
then strongly suggesting us LL-37 may be involved in the
pathogenesis of COPD. Lung tissues come from COPD
patients receiving operation because of lung cancer, lung
bullae, lung cyst. Lung cancer was not excluded because of
the following two reasons. First, patients receiving opera-
tion because of benign lesions are limited. Second, there
was just one paper showed that LL-37 is expressed mostly in
adenocarcinoma and squamous cell carcinoma while the
expression in adjacent lung tissue is not reported.30
What role does LL-37 play in the development and
progression of COPD? What is the exact mechanism? We
subsequently carried out some in vitro study. Cigarette
smoking and infection were two main generally accepted
causes of COPD. Bronchial epithelial cell and alveolar
epithelial cell, as important component of respiratory
immune system, are widespread and large in quantity. They
are the first barrier existing external stimulation and
exposed noxious particles or gases in the pathogenic
process of COPD. So in vitro we selected CSE and LPS. The
results of immunofluorescence staining showed that expo-
sure to CSE or LPS can enhance the expression of LL-37. This
results together with that in induced sputum and lung tissue
showed that LL-37 may be involved in the pathogenic
process of COPD.
What is the effect of the elevated LL-37 on lung cells?
We investigated whether LL-37 could directly influence
cytokines secretion. IL-8 and TNF-a are two important
generally accepted inflammatory markers in COPD, and
their concentration in induced sputum is considered to be
good biomarkers for disease activity and progression in
COPD.31 Our results suggested that the secretion of IL-8 in
Figure 4 Effect of CSE or LPS on the expression of LL-37. (1A) Expression of LL-37 on BEP2D before incubated with CSE.
(1B)(1C)(1D) Expression of LL-37 on BEP2D after incubated 24 h with 0.02, 0.04, 0.06 cig/ml of CSE. (2A) Expression of LL-37 on A549
before incubated with CSE. (2B)(2C)(2D) Expression of LL-37 on A549 after incubated 24 h with 0.02, 0.04, 0.06 cig/ml of CSE. (3A)
Expression of LL-37 on BEP2D before incubated with LPS. (3B) (3C)(3D) Expression of LL-37 on BEP2D after incubated 24 h with 10,
20, 30 mg/ml of LPS. (4A) Expression of LL-37 on A549 before incubated with LPS. (4B)(4C)(4D) Expression of LL-37 on A549 after
incubated 24 h with 10, 20, 30 mg/ml of LPS.
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induced after exposure to LL-37 synthesis polypeptide
while the secretion of TNF-a was not effected by LL-37
synthesis polypeptide. Scotts’ gene array studies indi-
cated that LL-37 directly up-regulates 29 genes which
encoding chemokines and chemokine receptors.7 Consis-
tent with this, LL-37 up-regulated the expression of che-
mokines in several different cells which included
macrophages and the mouse lung (monocyte chemo-
attractant protein 1), human A549 epithelial cells (IL-8),
and whole human blood (monocyte chemoattractant
protein 1 and IL-8).7 According to the literature and our
results, we speculate that LL-37 may induce respiratory
epithelium cell to produce IL-8, which could in turn recruit
additional immune cells to the sites of airway. This made
the inflammation of COPD become persistent and irrevers-
ible chronic inflammation state which can be still exist
without external stimulation.
Research shows that lung epithelium is the primary site
of lung damage in various lung diseases. Epethelial cellapoptosis has been considered to be initial event and is
followed by remodeling processes. More and more
evidences suggest that apoptosis is involved in initial injury
and defective repair in COPD.32,33 For example, endothelial
and epithelial cell apoptosis have been implicated as one of
important mechanisms of pulmonary emphysema. Intra-
tracheal injection of activated caspase-3 induces epithelial
cell apoptosis, enhances elastolytic activity, and subse-
quently induces emphysematous changes in mice.34e36 Our
results showed that LL-37 synthesis polypeptide can
induced apoptosis of bronchial epithelial cell and alveolar
epithelial cell, which might be a possible mechanism of LL-
37 involved in the development of COPD.
In conclusion, increased induced sputum levels of LL-37
in COPD patients were associated with airflow limitation,
health status and exercise tolerance and expressing inten-
sity of LL-37 in both airway area and pulmonary alveoli area
in COPD group significantly increased compared with
control group. These results suggested that LL-37 may be
a valid biomarker for disease activity and progression in
Figure 5 Effects of LL-37 synthesis polypeptide on the release of IL-8 and TNF-a of BEP2D and A549. A IL-8 in supernatant of BEP2D
and A549 cells after treated with the indicated doses of LL-37 for 24 h. B TNF-a in supernatant of BEP2D and A549 cells after treated
with the indicated doses of LL-37 for 24 h. C IL-8 in supernatant of BEP2D and A549 cells after treated with 20 mg/ml of LL-37 for 6 h,
12 h, 24 h, 48 h. D TNF-a in supernatant of BEP2D and A549 cells after treated with 20 mg/ml of LL-37 for 6 h, 12 h, 24 h, 48 h.
Figure 6 Effect of LL-37 synthesis polypeptide on apoptosis of BEP2D and A549. A BEP2D cells were treated with the indicated
doses of LL-37 for 24 h. B BEP2D cells were treated with 50 mg/ml of LL-37 for 1 h, 6 h, 12 h, 24 h. C A549 cells were treated with the
indicated doses of LL-37 for 24 h. D A549 cells were treated with 50 mg/ml of LL-37 for 1 h, 6 h, 12 h, 24 h.
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1688 Y.-Y. Jiang et al.COPD. Through stimulation by CSE and LPS, the expression
of LL-37 was increased in bronchial epithelial cell and
alveolar epithelial cell. LL-37 synthesis polypeptide can
induce apoptosis of bronchial epithelial cell and alveolar
epithelial cell and promote the releasing of inflammatory
factor, suggesting that LL-37 may play important role in the
pathogenesis of COPD.Acknowledgments
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